These four small-cap stocks scan as deeply undervalued right now.
The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for the next up-and-comer. And within this popular market are stocks that are valued well below their potential. These three biotech stocks have some of the most promising treatments awaiting approval. But they aren’t trading at a value reflective of the likely explosive future growth. Investors should
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.